| 摘要 |
PROBLEM TO BE SOLVED: To provide a radiotherapy enhancing agent effective against radiation resistant cancer, and a therapeutic method of radiation resistant cancer using the radiotherapy enhancing agent.SOLUTION: A radiotherapy enhancing agent to radiation resistant cancer having an Arf6-AMAP1-PRKD2 pathway contains nucleic acid that inhibits expression of protein selected from the group consisting of Arf6, AMAP1, PRKD2, GEP100 and Rab5c, which is included in the Arf6-AMAP1-PRKD2 pathway, as an active ingredient. An radiotherapy enhancing agent to radiation resistant cancer having the Arf6-AMAP1-PRKD2 pathway wherein radiation resistant cancer further has a mevalonate pathway, and the enhancing agent contains a substance that inhibits an activity of enzyme included in the mevalonate pathway as an active ingredient. A radiotherapy method includes administering a radiotherapy enhancing agent, which contains nucleic acid that inhibits expression of protein selected from the group consisting of Arf6, AMAP1, PRKD2, GEP100 and Rab5c, which is included in the Arf6-AMAP1-PRKD2 pathway (or a substance that inhibits the activity of enzyme included in the mevalonate pathway), as an active ingredient, to a patient before and/or under radiotherapy to radiation resistant cancer having the Arf6-AMAP1-PRKD2 pathway (and mevalonate pathway). |
